- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Acute myeloid leukaemia
- Meeting Date: July 2024
- Public Summary Document (PSD) July 2024 PBAC Meeting - (PDF 420KB)
- Public Summary Document (PSD) July 2024 PBAC Meeting - (Word 53KB)
Daunorubicin with cytarabine – July 2024
Daunorubicin With Cytarabine: Powder for I.V infusion containing daunorubicin 44 mg and cytarabine 100 mg; Vyxeos®
Last updated
30 May 2025